secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revance Therapeutics, Inc. (—)
CIK:        0001479290
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001193125-23-237318
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 2.06, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revance to exit OPUL payments business, record up to $100M impairment, revise guidance
--------------------------------------------------------------------------------

- Exiting OPUL payments business, expects to free up ~$20M/year for reinvestment; restructuring charges up to $7M, non-cash impairment $80M-$100M.
- Revised 2023 GAAP OpEx guidance to $545M-$585M (from $460M-$480M); Non-GAAP OpEx narrowed to $315M-$335M.
- New DAXXIFY pricing program effective Sept 1, 2023; expects adjusted gross margin over 80% long-term.
- Cash of $319.7M at June 30, plus $50M notes from Athyrium in Aug; funded to breakeven, adjusted EBITDA positive expected in 2025.
- Q3 product revenue expected around Q2 levels due to new pricing and seasonality; product revenue guidance in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479290/000119312523237318/0001193125-23-237318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479290/000119312523237318/d549881d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-237318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer